CD274 and non-small cell lung carcinoma: The levels of the PD-1 inhibitory receptor on tumor-infiltrating T cells, along with those of its ligand, PD-L-1, on tumor and infiltrating myeloid cells are associated with responsiveness to ICI immunotherapies in NSCLC patients [27].